Wall Street trims can­cer drug de­vel­op­er BioN­Tech's uni­corn val­u­a­tion

Mar­ket con­di­tions in the Unit­ed States are spook­ing in­vestors. Af­ter ADC Ther­a­peu­tics re­scind­ed its plans ear­li­er this month for a pub­lic list­ing — cit­ing an ad­verse …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.